This hospital-based, multicenter, randomized, placebo-controlled trial will assess the
effects of misoprostol as part of active management of the third stage of labor on postpartum
blood loss, complications, and side effects. Twelve hundred eligible women will receive
routine oxytocics (oxytocin 5-10 IU) plus either 400 mcg sublingual misoprostol or placebo
during or immediately after delivery. The primary outcome will be measured blood loss of
=>500 mls within one hour after enrollment.
Phase:
N/A
Details
Lead Sponsor:
Gynuity Health Projects
Collaborators:
Effective Care Research Unit Effective Care Research Unit, South Africa Family Care International University of Witwatersrand, South Africa